JP2016172781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016172781A5 JP2016172781A5 JP2016136149A JP2016136149A JP2016172781A5 JP 2016172781 A5 JP2016172781 A5 JP 2016172781A5 JP 2016136149 A JP2016136149 A JP 2016136149A JP 2016136149 A JP2016136149 A JP 2016136149A JP 2016172781 A5 JP2016172781 A5 JP 2016172781A5
- Authority
- JP
- Japan
- Prior art keywords
- revascularization
- composition
- hours
- subject
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 13
- 230000000250 revascularization Effects 0.000 claims 11
- 230000002792 vascular Effects 0.000 claims 6
- 210000001519 tissues Anatomy 0.000 claims 5
- 206010018987 Haemorrhage Diseases 0.000 claims 3
- 230000000740 bleeding Effects 0.000 claims 3
- 231100000319 bleeding Toxicity 0.000 claims 3
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 claims 2
- 102000013566 Plasminogen Human genes 0.000 claims 2
- 108010051456 Plasminogen Proteins 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229960000103 thrombolytic agents Drugs 0.000 claims 2
- 210000004204 Blood Vessels Anatomy 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 229940012957 Plasmin Drugs 0.000 claims 1
- 108010023197 Streptokinase Proteins 0.000 claims 1
- 229960005202 Streptokinase Drugs 0.000 claims 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 claims 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 claims 1
- 229960005356 Urokinase Drugs 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 230000000271 cardiovascular Effects 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 230000000896 plasminic Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 108010073863 saruplase Proteins 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 1
Claims (11)
- 治療有効量のペプチドＤ−Ａｒｇ−２’，６’−Ｄｍｔ−Ｌｙｓ−Ｐｈｅ−ＮＨ 2 又はその薬学的に許容可能な塩を含む、出血領域の予防又は処置を必要とする哺乳動物である対象における出血領域の予防又は処置で使用するための組成物。
- 前記対象が血管再建術を受ける、請求項１に記載の組成物。
- 前記対象が、心血管組織、骨格筋組織、脳組織及び腎組織から成る群から選択される組織に関連した出血領域を抱えている、請求項１に記載の組成物。
- 前記対象に、前記ペプチドを、前記血管再建術の前に、前記血管再建術の後に、前記血管再建術の最中及び後に又は前記血管再建術の前、最中及び後に連続的に投与する、請求項２に記載の組成物。
- 前記対象に、前記ペプチドを、前記血管再建術後の少なくとも３時間、前記血管再建術後の少なくとも５時間、前記血管再建術後の少なくとも８時間、前記血管再建術後の少なくとも１２時間又は前記血管再建術後の少なくとも２４時間にわたって投与する、請求項４に記載の組成物。
- 前記対象に、前記ペプチドを、前記血管再建術の少なくとも８時間前から、前記血管再建術の少なくとも４時間前から、前記血管再建術の少なくとも２時間前から、前記血管再建術の少なくとも１時間前から又は前記血管再建術の少なくとも１０分前から投与する、請求項４に記載の組成物。
- 前記対象が心筋梗塞又は脳卒中を患っている、あるいは血管形成術を必要としている、請求項１に記載の組成物。
- 前記血管再建術が、バルーン血管形成術、バイパスグラフトの挿入、ステントの挿入、経皮的冠動脈形成術及び方向性冠動脈アテレクトミーから成る群から選択される、請求項２に記載の組成物。
- 前記血管再建術が閉塞の除去である、請求項２に記載の組成物。
- 前記血管再建術が１種以上の血栓溶解薬の投与である、請求項２に記載の組成物。
- 前記１種以上の血栓溶解薬が、組織プラスミノーゲンアクチベータ、ウロキナーゼ、プロウロキナーゼ、ストレプトキナーゼ、プラスミノーゲンのアシル化形態、プラスミンのアシル化形態及びアシル化ストレプトキナーゼ／プラスミノーゲン複合体から成る群から選択される、請求項１０に記載の組成物。
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36312910P | 2010-07-09 | 2010-07-09 | |
| US36313310P | 2010-07-09 | 2010-07-09 | |
| US61/363,133 | 2010-07-09 | ||
| US61/363,129 | 2010-07-09 | ||
| US41265510P | 2010-11-11 | 2010-11-11 | |
| US61/412,655 | 2010-11-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518868A Division JP6319738B2 (ja) | 2010-07-09 | 2011-07-08 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000305A Division JP2019052188A (ja) | 2010-07-09 | 2019-01-04 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016172781A JP2016172781A (ja) | 2016-09-29 |
| JP2016172781A5 true JP2016172781A5 (ja) | 2017-03-16 |
Family
ID=45441572
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518868A Active JP6319738B2 (ja) | 2010-07-09 | 2011-07-08 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
| JP2016136149A Pending JP2016172781A (ja) | 2010-07-09 | 2016-07-08 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
| JP2019000305A Pending JP2019052188A (ja) | 2010-07-09 | 2019-01-04 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
| JP2020080135A Pending JP2020114880A (ja) | 2010-07-09 | 2020-04-30 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
| JP2021181839A Pending JP2022012924A (ja) | 2010-07-09 | 2021-11-08 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518868A Active JP6319738B2 (ja) | 2010-07-09 | 2011-07-08 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000305A Pending JP2019052188A (ja) | 2010-07-09 | 2019-01-04 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
| JP2020080135A Pending JP2020114880A (ja) | 2010-07-09 | 2020-04-30 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
| JP2021181839A Pending JP2022012924A (ja) | 2010-07-09 | 2021-11-08 | 虚血／再灌流障害に続くノーリフローの予防又は処置方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9345738B2 (ja) |
| EP (3) | EP3539554A1 (ja) |
| JP (5) | JP6319738B2 (ja) |
| CN (4) | CN105879008A (ja) |
| CA (1) | CA2804404C (ja) |
| HK (1) | HK1249428A1 (ja) |
| WO (1) | WO2012006569A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2788013A4 (en) * | 2011-12-09 | 2015-08-19 | Stealth Peptides Int Inc | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
| EP3078384A1 (en) * | 2012-02-22 | 2016-10-12 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| AU2013237827B2 (en) * | 2012-03-30 | 2017-12-14 | Stealth Biotherapeutics Inc. | Methods and compositions for the prevention and treatment neuropathy |
| EP3586864A1 (en) * | 2013-05-14 | 2020-01-01 | Stealth Biotherapeutics Corp | Methods for the prevention or treatment of left ventricle remodeling |
| US10293020B2 (en) | 2013-06-27 | 2019-05-21 | Stealth Biotherapeutics Corp. | Peptide therapeutics and methods for using same |
| US11724030B2 (en) * | 2018-09-21 | 2023-08-15 | Corflow Therapeutics Ag | Method and apparatus for diagnosis and treatment of microvascular dysfunction |
| EP3442990A4 (en) | 2016-04-11 | 2019-12-18 | Carnot, LLC | CHIRAL PEPTIDES |
| CN110914287A (zh) | 2017-04-05 | 2020-03-24 | 隐形生物治疗公司 | Boc-d-arg-dmt-lys-(boc)-phe-nh2的结晶盐形式 |
| US11795196B2 (en) | 2017-12-15 | 2023-10-24 | Stealth Biotherapeutics Inc. | Mitochondria-targeting peptides |
| FI3723783T3 (fi) * | 2017-12-15 | 2023-03-24 | Stealth Biotherapeutics Inc | Mitokondrioon kohdentuvia peptidejä |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| EP3898653A4 (en) * | 2018-12-18 | 2022-08-24 | Stealth BioTherapeutics Inc. | ANALOGS TARGETING MITOCHONDRIAL DISEASES |
| CN113544138A (zh) * | 2018-12-18 | 2021-10-22 | 隐形生物治疗公司 | 线粒体靶向肽 |
| EP3943182A4 (en) | 2019-03-20 | 2022-05-25 | Mitsubishi Chemical Corporation | POLYMER, SEPARATION AGENT, POLYMER PRODUCTION METHOD, COMPOUND SEPARATION METHOD AND COMPOUND PRODUCTION METHOD |
| RU2711414C1 (ru) * | 2019-03-27 | 2020-01-17 | Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) | Способ прогнозирования асимптомного повреждения вещества головного мозга при ангиореконструктивных операциях на сонных артериях |
| JP2022542882A (ja) | 2019-07-24 | 2022-10-07 | ステルス バイオセラピューティクス インコーポレイテッド | 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド |
| JP7478453B2 (ja) * | 2022-01-31 | 2024-05-07 | 株式会社ニューギン | 遊技機 |
| JP7533970B2 (ja) * | 2022-01-31 | 2024-08-14 | 株式会社ニューギン | 遊技機 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5182106A (en) | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| JPH05301868A (ja) | 1992-04-23 | 1993-11-16 | Mitsui Toatsu Chem Inc | 虚血性心疾患治療剤 |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| ATE413414T1 (de) | 2002-08-01 | 2008-11-15 | Astellas Pharma Inc | Kaliumabhängiger natrium-calcium-austauscher |
| AU2005208821B8 (en) * | 2003-02-04 | 2010-10-14 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| CN102617706A (zh) * | 2003-02-04 | 2012-08-01 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| CN101296704B (zh) * | 2005-09-16 | 2012-09-05 | 科内尔研究基金会 | 用于减少cd36表达的方法 |
| CN102791280A (zh) * | 2009-12-31 | 2012-11-21 | 康肽德生物医药技术有限公司 | 用于预防或治疗血管阻塞损伤的方法 |
| CN103830719A (zh) * | 2009-12-31 | 2014-06-04 | 康肽德生物医药技术有限公司 | 用于进行冠状动脉旁路移植手术的方法 |
| WO2011116007A1 (en) * | 2010-03-15 | 2011-09-22 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
-
2011
- 2011-07-08 WO PCT/US2011/043424 patent/WO2012006569A1/en active Application Filing
- 2011-07-08 EP EP19157391.4A patent/EP3539554A1/en not_active Withdrawn
- 2011-07-08 CN CN201510122649.5A patent/CN105879008A/zh not_active Withdrawn
- 2011-07-08 JP JP2013518868A patent/JP6319738B2/ja active Active
- 2011-07-08 EP EP11804436.1A patent/EP2590664B1/en active Active
- 2011-07-08 EP EP23185558.6A patent/EP4285994A3/en active Pending
- 2011-07-08 CN CN2011800429365A patent/CN103249423A/zh active Pending
- 2011-07-08 CA CA2804404A patent/CA2804404C/en active Active
- 2011-07-08 CN CN201610616831.0A patent/CN106620645A/zh active Pending
- 2011-07-08 CN CN201710574500.XA patent/CN107569675A/zh active Pending
- 2011-07-08 US US13/808,027 patent/US9345738B2/en active Active
-
2016
- 2016-05-18 US US15/158,005 patent/US10322159B2/en active Active
- 2016-07-08 JP JP2016136149A patent/JP2016172781A/ja active Pending
-
2018
- 2018-07-12 HK HK18109055.3A patent/HK1249428A1/zh unknown
-
2019
- 2019-01-04 JP JP2019000305A patent/JP2019052188A/ja active Pending
-
2020
- 2020-04-30 JP JP2020080135A patent/JP2020114880A/ja active Pending
-
2021
- 2021-11-08 JP JP2021181839A patent/JP2022012924A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016172781A5 (ja) | ||
| JP2013531682A5 (ja) | ||
| JP2013516425A5 (ja) | ||
| Archundia et al. | Direct cardiac injection of G-CSF mobilized bone-marrow stem-cells improves ventricular function in old myocardial infarction | |
| Memon et al. | Safety and feasibility of intraarterial eptifibatide as a revascularization tool in acute ischemic stroke | |
| Liu et al. | Catheter-directed thrombolysis for acute iliofemoral deep venous thrombosis | |
| Yang et al. | Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment | |
| AR033658A1 (es) | Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento d | |
| Ristalli et al. | Intravascular lithotripsy and Impella support to assist complex LM angioplasty | |
| Wilhelm et al. | Controlled reperfusion using a simplified perfusion system preserves function after acute and persistent limb ischemia: a preliminary study | |
| Amemiya et al. | Usefulness of oral Xa inhibitor for management of ischemic stroke associated with thrombosis in the pulmonary vein stump after lung resection | |
| Blum et al. | Endovascular management of acute deep vein thrombosis | |
| Marietta et al. | Is there a role for intervention radiology for the treatment of lower limb deep vein thrombosis in the era of direct oral anticoagulants? A comprehensive review | |
| Pierot et al. | Teaching lessons by MR CLEAN | |
| Krakovsky et al. | THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models | |
| Moses et al. | Do new devices add to the results of PTCA in acute myocardial infarction? | |
| Harrington | Thrombolytic therapy in renal vein thrombosis | |
| Zahger et al. | Thrombolysis in the era of the randomized trials | |
| Gupta et al. | Bilateral Catheter-Directed Thrombolysis for an Acute Bilateral Pulmonary Embolism Patient with Severe Right Ventricular Strain: from Intensive Care Unit to Home on Postoperative Day 1. | |
| Spratt et al. | Pulmonary transplant salvage using ultrasound-assisted thrombolysis of subacute occlusive main pulmonary artery embolus | |
| Hinohara | Percutaneous coronary intervention: current perspective | |
| Blankenship et al. | Acute myocardial infarction complicating urokinase infusion for total saphenous vein graft occlusion | |
| Dziewierz et al. | Local administration of abciximab using a ClearWay RX infusion catheter in a patient with acute coronary syndrome caused by late in− stent thrombosis | |
| Hokimoto et al. | Initial and mid-term outcomes of pulse infusion thrombolysis using a unique pump system and stent placement for deep vein thrombosis | |
| US20220265291A9 (en) | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices |